[1] RIAZ W, ZHANG L, HORNA P, et al. Blastic plasmacytoid dendritic cell neoplasm: update on molecular biology, diagnosis, and therapy[J].Cancer Control,2014,21(4):279-289. [2] TSAGARAKIS N J, PATERAKIS G. Dendritic cell leukemia: a review[J].Curr Oncol Rep,2020,22(6):55. [3] ADNAN A, POWELL P R, STAPLES C J, et al. Blastic plasmacytoid dendritic cell neoplasm: a case series and review[J].Am J Dermatopathol,2021. [4] ZHANG Y, XIONG J, LI S, et al. Cutaneous manifestations of blastic plasmacytoid dendritic cell neoplasm: a retrospective study of morphological and immunophenotypic features[J].Eur J Dermatol,2022,32(1):70-76. [5] AOKI T, SUZUKI R, KUWATSUKA Y, et al. Long-term survival following autologous and allogeneic stem cell transplantation for blastic plasmacytoid dendritic cell neoplasm[J].Blood,2015,125(23):3559-3562. [6] KERR D N, SOKOL L. The advances in therapy of blastic plasmacytoid dendritic cell neoplasm[J].Expert Opin Investig Drugs,2018,27(9):733-739. [7] VENUGOPAL S, ZHOU S, EL J S, et al. Blastic plasmacytoid dendritic cell neoplasm-current insights[J].Clin Lymphoma Myeloma Leuk,2019,19(9):545-554. [8] JEGALIAN A G, BUXBAUM N P, FACCHETTI F, et al. Blastic plasmacytoid dendritic cell neoplasm in children: diagnostic features and clinical implications[J].Haematologica,2010,95(11):1873-1879. [9] SWEET K. Blastic plasmacytoid dendritic cell neoplasm: diagnosis, manifestations, and treatment[J].Curr Opin Hematol,2020,27(2):103-107. [10] SULLIVAN J M, RIZZIERI D A. Treatment of blastic plasmacytoid dendritic cell neoplasm[J].Hematology Am Soc Hematol Educ Program,2016,2016(1):16-23. [11] SAPIENZA M R, PILERI A, DERENZINI E, et al.Blastic plasmacytoid dendritic cell neoplasm: state of the art and prospects[J].Cancers (Basel),2019,11(5). [12] PETRELLA T, BAGOT M, WILLEMZE R, et al. Blastic NK-cell lymphomas (agranular CD4+CD56+ hematodermic neoplasms): a review[J].Am J Clin Pathol,2005,123(5):662-675. [13] TESTA U, PELOSI E, CASTELLI G. CD123 as a therapeutic target in the treatment of hematological Malignancies[J].Cancers (Basel),2019,11(9): 1358. [14] CERIBELLI M, HOU Z E, KELLY P N, et al. A Druggable TCF4- and BRD4-Dependent transcriptional network sustains malignancy in blastic plasmacytoid dendritic cell neoplasm[J].Cancer Cell,2016,30(5):764-778. [15] 吴灵珍,于倩,蒋谊,等. 母细胞性浆细胞样树突细胞肿瘤患者的临床特点[J].中国实验血液学杂志,2020,28(1):307-313. [16] BEIRD H C, KHAN M, WANG F, et al. Features of non-activation dendritic state and immune deficiency in blastic plasmacytoid dendritic cell neoplasm (BPDCN)[J].Blood Cancer J,2019,9(12):99. [17] LARIBI K, DENIZON N, BESANCON A, et al. Blastic plasmacytoid dendritic cell neoplasm: from origin of the cell to targeted therapies[J].Biol Blood Marrow Transplant,2016,22(8):1357-1367. [18] DIPIPPO A J, WILSON N R, PEMMARAJU N. Targeting CD123 in BPDCN: an emerging field[J].Expert Rev Hematol,2021,14(11):993-1004. [19] SHI Y, WANG E. Blastic plasmacytoid dendritic cell neoplasm: a clinicopathologic review[J].Arch Pathol Lab Med,2014,138(4):564-569. |